asa glp 1 agonist guidelines GLP-1 medications safe to continue before surgery in patients with diabetes and obesity Anesthetic Considerations for Patients Taking
Description
As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)

By 2030, the global prevalence of obesity is expected to reach one billion

Learn what Toujeo actually is, how insulin glargine differs from GLP-1 agonists like semaglutide, and why the distinction matters.
Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile
